As a risk factor for coronary artery disease, PCSK9 elevates LDL-C levels in plasma by binding to the extracellular domain of LDLR in hepatocytes to mediate LDLR endocytosis and degradation in hepatic lysosomes (34). Here, LDLR is linked to coronary artery disorder.